Patisiran's path to approval as an RNA therapy
- PMID: 31619801
- DOI: 10.1038/d41586-019-03070-w
Patisiran's path to approval as an RNA therapy
Keywords: Drug discovery; Therapeutics.
Comment on
-
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153. N Engl J Med. 2018. PMID: 29972753 Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources